PO Box 1488
Warrenville, IL 60555
Phone: 331.248.7888
Email: sidp@affinity-strategies.com
Ring in the end of the year with our Breakpoints hosts and a review of all things IDWeek 2025! Join Drs. Erin McCreary, Julie Ann Justo, Whitney Buckel, and Ryan Moenster as they cover top late breaking abstracts, new stewardship data, practice-changing clinical trials, and much more.
How to Obtain BCIDP Recertification Credit for this Episode: Visit sidp.org/BCIDP for more information
- Andes DR, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient‑level quantitative review of randomized trials. Clin Infect Dis. 2012;54(8):1110‑1122. https://pubmed.ncbi.nlm.nih.gov/22412055/
- Carmeli Y, Cisneros JM, Paul M, et al. Aztreonam‑avibactam versus meropenem for the treatment of serious infections caused by Gram‑negative bacteria (REVISIT): a descriptive, multinational, open‑label, phase 3, randomized trial. Lancet Infect Dis. 2025;25(2):218‑230. [unboundmedicine.com]
- Cornely OA, Sprute R, Bassetti M, et al. Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM. Lancet Infect Dis. 2025;25(5):e280‑e293. [pubmed.ncb…lm.nih.gov]
- GSK. PIVOT‑PO phase III study for tebipenem HBr stopped early for efficacy following review by Independent Data Monitoring Committee. Published May 28, 2025. [gsk.com]
- Ong SWX, Pinto R, Rishu A, et al. Identifying heterogeneity of treatment effect for antibiotic duration in bloodstream infection: an exploratory post‑hoc analysis of the BALANCE randomized clinical trial. EClinicalMedicine. 2025;83:103195. [experts.mcmaster.ca]
- Paciulli M, et al. Real‑world evaluation of ceftriaxone‑related safety events: a stewardship call to action. ASHE. 2026. https://pubmed.ncbi.nlm.nih.gov/41497435/
- Paterson DL, et al. Cefiderocol versus standard therapy for hospital‑acquired and healthcare‑associated Gram‑negative bacterial bloodstream infection (GAME CHANGER trial): an open‑label, parallel‑group, randomized trial. Lancet Infect Dis. 2025. https://pubmed.ncbi.nlm.nih.gov/41067237/
- Ross JDC, et al. Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE‑1): a phase 3 randomized, open‑label, non‑inferiority, multicentre study. Lancet. 2025;405(10489):1608‑1620. https://pubmed.ncbi.nlm.nih.gov/40245902/
- Shafat T, Ariza‑Heredia EJ, Daher M, Chemaly RF. How we diagnose and manage refractory and resistant herpes simplex virus mucocutaneous infection after haematopoietic cell transplantation. Clin Microbiol Infect. 2025;31(5):761‑772. [clinicalmi…ection.org]
- Turner RB, et al. Dalbavancin for treatment of Staphylococcus aureus bacteremia: the DOTS randomized clinical trial. JAMA. 2025. https://pubmed.ncbi.nlm.nih.gov/40802264/
- Vodstrcil LA, et al. Male‑partner treatment to prevent recurrence of bacterial vaginosis. N Engl J Med. 2025;392(10):947‑957. https://pubmed.ncbi.nlm.nih.gov/40043236/
- Walls G, McGrath L, Herdman MT, et al. Patient‑reported perceptions, experiences and preferences around intravenous and oral antibiotics for the treatment of Staphylococcus aureus bacteremia: a descriptive qualitative study. Clin Infect Dis. Published September 24, 2025. doi:10.1093/cid/ciaf522. [pubmed.ncb…lm.nih.gov]
Is it possible to get the power point for the presentation ? varduhil.arabyan@hpmedcenter.com
Hello! This episode does not have an associated PowerPoint presentation.
Thank you guys so much for this comprehensive overview of ID WEEK! I love this episode.
Is it possible to put links or references in the show notes? Thanks, Robbert.